Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Mari Mino-Kenudson, M.D.

Co-Author

This page shows the publications co-authored by Mari Mino-Kenudson and David Ryan.
Connection Strength

0.395
  1. Results and Molecular Correlates from a Pilot Study of Neoadjuvant Induction FOLFIRINOX Followed by Chemoradiation and Surgery for Gastroesophageal Adenocarcinomas. Clin Cancer Res. 2021 Jul 30.
    View in: PubMed
    Score: 0.061
  2. Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes. Pancreatology. 2021 May 15.
    View in: PubMed
    Score: 0.060
  3. A Combination of Biochemical and Pathological Parameters Improves Prediction of Postresection Survival After Preoperative Chemotherapy in Pancreatic Cancer: The PANAMA-score. Ann Surg. 2020 Jul 07.
    View in: PubMed
    Score: 0.057
  4. Impact of adjuvant therapy in patients with invasive intraductal papillary mucinous neoplasms of the pancreas. Pancreatology. 2020 Jun; 20(4):722-728.
    View in: PubMed
    Score: 0.055
  5. Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism. Nat Cell Biol. 2018 07; 20(7):811-822.
    View in: PubMed
    Score: 0.049
  6. Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival. PLoS One. 2017; 12(8):e0182855.
    View in: PubMed
    Score: 0.046
  7. Phase I study of preoperative short-course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic ductal adenocarcinoma of the head. Int J Radiat Oncol Biol Phys. 2011 Jan 01; 79(1):151-7.
    View in: PubMed
    Score: 0.028
  8. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol. 2005 Nov 01; 23(31):8136-9.
    View in: PubMed
    Score: 0.020
  9. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004 Feb; 10(2):145-7.
    View in: PubMed
    Score: 0.018
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.